Today saw a cluster of FDA regulatory catalysts across biotech. Regeneron received FDA Priority Review for cemdisiran, an investigational siRNA therapy for generalized myasthenia gravis (gMG) with a target action date in November 2026 — potentially the first siRNA approved for gMG. Palvella Therapeutics announced FDA rolling review for QTORIN rapamycin for microcystic lymphatic malformations. TScan Therapeutics presented positive Phase 1 Cohort C data for TSC-101. These events highlight momentum in the biotech regulatory pipeline.
RUNNING Biotech FDA Pipeline Catalysts
STRENGTH 50
Multiple biotech companies land FDA regulatory milestones today including Regeneron's Priority Review for a first-in-class siRNA therapy
RUNNING Nuclear Power for AI Data Centers
STRENGTH 50
Reddit and social sentiment surge around nuclear and utility names as AI data center power demand thesis continues gaining traction
Social sentiment data shows a cluster of nuclear and utility stocks being discussed together on Reddit — Constellation Energy, Vistra, Talen Energy, Oklo, and others. The structural thesis is that AI data center buildout is driving enormous electricity demand, which benefits nuclear-powered utilities and next-generation nuclear developers. While established operators like CEG and VST have already run on this theme, smaller nuclear developers like Oklo have less momentum and could see catch-up flows as the narrative broadens.